AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR

 
• By Alaric DeArment
Lung Cancer
AstraZeneca announced data for Imfinzi in neoadjuvant/adjuvant non-small cell lung cancer at AACR • Source: Shutterstock

More from Clinical Trials

More from R&D